We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Neutrophil to lymphocyte ratio and peripheral blood biomarkers correlate with survival outcomes but not response among head and neck and salivary cancer treated with pembrolizumab and vorinostat.
- Authors
Pan, Cassie; Wu, Qian "Vicky"; Voutsinas, Jenna; Houlton, Jeffrey J.; Barber, Brittany; Futran, Neal; Laramore, George E.; Liao, Jay J.; Parvathaneni, Upendra; Martins, Renato G.; Fromm, Jonathan R.; Rodriguez, Cristina P.
- Abstract
Background: Associations between peripheral blood biomarkers and oncologic outcomes were explored in recurrent/metastatic (R/M) head and neck squamous cell carcinoma (HN) and salivary gland cancer (SGC) treated with pembrolizumab and vorinostat on a phase II trial (NCT02538510). Experimental Design: Twenty‐five HN and 25 SGCs were treated with pembrolizumab and vorinostat. Baseline peripheral blood was available in 21 HN and 20 SGCs and evaluated for associations with grade ≥3 adverse events (G ≥ 3AE) by CTCAEv4, objective response rate (ORR), overall survival (OS), and progression‐free survival (PFS). Results: Higher pretreatment neutrophil‐to‐lymphocyte ratio (NLR) and neutrophils, as well as lower pretreatment lymphocytes and T helper cells correlated with worse OS and PFS. Higher NLR further predicted increased rates of G ≥ 3AEs. No correlations with ORR were observed. Conclusions: In a prospectively evaluated cohort of HN and SGCs treated with pembrolizumab and vorinostat, we observed novel associations between peripheral blood biomarkers and oncologic outcomes and toxicities.
- Subjects
NEUTROPHIL lymphocyte ratio; HEAD &; neck cancer; SALIVARY gland cancer; SURVIVAL rate; T helper cells
- Publication
Head & Neck, 2023, Vol 45, Issue 2, p391
- ISSN
1043-3074
- Publication type
Article
- DOI
10.1002/hed.27252